News

Issued by Esperion, not Hls Therapeutics, Inc.

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

November 18, 2025 · Published on GlobeNewswire

It isn’t one of Hls Therapeutics, Inc.’s news releases, so 6ix doesn’t show it on Hls Therapeutics, Inc.’s page or send it as an alert.

Go to Hls Therapeutics, Inc. on 6ix